UBS Group’s NeuBase Therapeutics NBSE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-4,056
Closed -$1.82K – 10394
2024
Q1
$1.82K Sell
4,056
-61,668
-94% -$46.7K ﹤0.01% 8043
2023
Q4
$48.6K Buy
+65,724
New +$47.9K ﹤0.01% 6546
2023
Q3
– Sell
-68
Closed -$127 – 10163
2023
Q2
$127 Sell
68
-118
-63% -$389 ﹤0.01% 8470
2023
Q1
$689 Buy
+186
New +$859 ﹤0.01% 8927
2022
Q3
– Sell
-123
Closed -$3K – 11203
2022
Q2
$3K Buy
+123
New +$2.89K ﹤0.01% 9406
2022
Q1
– Sell
-372
Closed -$21K – 11133
2021
Q4
$21K Buy
372
+113
+44% +$7.59K ﹤0.01% 7804
2021
Q3
$19K Buy
259
+253
+4,217% +$19.4K ﹤0.01% 7234
2021
Q2
$1K Sell
6
-140
-96% -$15.5K ﹤0.01% 9219
2021
Q1
$22K Buy
146
+5
+4% +$906 ﹤0.01% 7306
2020
Q4
$19K Buy
141
+68
+93% +$11K ﹤0.01% 6995
2020
Q3
$11K Sell
73
-209
-74% -$34.1K ﹤0.01% 6795
2020
Q2
$49K Buy
282
+275
+3,929% +$46K ﹤0.01% 5879
2020
Q1
$1K Sell
7
-10
-59% -$1.32K ﹤0.01% 7826
2019
Q4
$2K Sell
17
-170
-91% -$19.9K ﹤0.01% 7870
2019
Q3
$19K Buy
187
+127
+212% +$12.5K ﹤0.01% 6774
2019
Q2
$4K Buy
60
+50
+500% +$2.83K ﹤0.01% 7471
2019
Q1
$0 Sell
10
-218
-96% -$10.4K ﹤0.01% 8290
2018
Q4
$8K Buy
228
+143
+168% +$10.4K ﹤0.01% 7367
2018
Q3
$7K Buy
85
+34
+67% +$2.56K ﹤0.01% 7352
2018
Q2
$4K Sell
51
-69
-58% -$6.02K ﹤0.01% 7577
2018
Q1
$11K Buy
120
+110
+1,100% +$16.4K ﹤0.01% 6823
2017
Q4
$7K Sell
10
-65
-87% -$25.1K ﹤0.01% 7252
2017
Q3
$22K Buy
75
+65
+650% +$17.7K ﹤0.01% 6384
2017
Q2
$2K Sell
10
-20
-67% -$5.37K ﹤0.01% 7409
2017
Q1
$10K Sell
30
-12
-29% -$5.56K ﹤0.01% 6626
2016
Q4
$25K Hold
42
– – ﹤0.01% 6381
2016
Q3
$48K Buy
42
+5
+14% +$5.39K ﹤0.01% 5557
2016
Q2
$40K Sell
37
-5
-12% -$6.28K ﹤0.01% 5691
2016
Q1
$54K Sell
42
-25
-37% -$35.6K ﹤0.01% 5447
2015
Q4
$165K Sell
67
-5
-7% -$7.68K ﹤0.01% 4821
2015
Q3
$80K Sell
72
-9
-11% -$10.4K ﹤0.01% 5413
2015
Q2
$82K Sell
81
-17
-17% -$18.3K ﹤0.01% 5576
2015
Q1
$100K Buy
98
+11
+13% +$36.3K ﹤0.01% 5418
2014
Q4
$290K Sell
87
-9
-9% -$27.6K ﹤0.01% 4684
2014
Q3
$278K Buy
96
+19
+25% +$62.8K ﹤0.01% 4844
2014
Q2
$294K Sell
77
-95
-55% -$358K ﹤0.01% 4769
2014
Q1
$935K Buy
172
+167
+3,340% +$880K ﹤0.01% 3551
2013
Q4
$15K Hold
5
– – ﹤0.01% 8529
2013
Q3
$15K Buy
5
+1
+25% +$2.73K ﹤0.01% 8402
2013
Q2
$13K Hold
4
– – ﹤0.01% 8370

Other funds holding NBSE

UBS Group's NBSE Position: Q2 2024 in Review

UBS Group sold out of NeuBase Therapeutics (NBSE) in Q2 2024, closing a stake of 4,056 shares — an estimated $1.82K sold.

UBS Group first reported a position in NBSE in Q2 2013 and held it in 40 quarters. The position peaked at $935K in Q1 2014. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.

  • UBS Group reported no remaining NeuBase Therapeutics position as of Q2 2024 after selling out during the quarter.
  • UBS Group sold 4,056 NeuBase Therapeutics shares in Q2 2024, an estimated $1.82K.
  • UBS Group first reported a position in NeuBase Therapeutics in Q2 2013 and held it in 40 quarters.
  • UBS Group's NeuBase Therapeutics position peaked at $935K in Q1 2014.
  • 3 funds tracked by Wall St. Rank held NeuBase Therapeutics as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.